Allergan CEO Brent Saunders told CNBC on Wednesday the U.S. government had targeted his company's failed $160 billion deal with Pfizer.
"It really looked like they did a very fine job of constructing a rule here — a temporary rule — to stop this deal, and obviously it was successful," he told CNBC's "Squawk on the Street."
Saunders was referring to
Saunders singled out the provision in the rules that imposes a three-year limit on foreign companies bulking up on U.S. assets to avoid ownership requirements for a later inversions deal. He said that ban in particular was designed to block the Pfizer-Allergan deal.
Allergan had been blindsided by Treasury's announcement, Saunders said.
"For the rules to be changed after the game has started to be played is a bit un-American, but that's the situation we're in," he said.
"We built this deal around the law, the regulations, all the notices that were put out by the Treasury and it was a highly legal construct," he added. "We followed the rules that Congress had set for companies looking to move to foreign domicile."